SEC Contract Filing

Filing Date: 2016-08-08

Document Content:
<DOCUMENT>
<TYPE>EX-10.26XXVI
<SEQUENCE>3
<FILENAME>fgen-ex1026xxvi_113.htm
<DESCRIPTION>EX-10.26XXVI
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex1026xxvi_113.htm
</title>
</head>
<!-- NG Converter v4.0.3.7 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended.</p>
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.26(xxvi)</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:-0.11%;font-weight:bold;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">Amendment No. 24 to the Process Development and Clinical Supply Agreement</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">This Amendment No. 24 <font style="font-weight:normal;font-variant: normal;">(the &#8220;24th Amendment&#8221;), retroactively effective as of September 15, 2015 (the &#8220;24th Amendment Effective Date&#8221;) by and between </font><font style="font-variant: normal;">Boehringer Ingelheim Biopharmaceuticals GmbH</font><font style="font-weight:normal;font-variant: normal;">, Binger Str. 173, 55216 Ingelheim, Germany (&#8220;BI&#8221;) and </font><font style="font-variant: normal;">FibroGen, Inc.</font><font style="font-weight:normal;font-variant: normal;">, 409 Illinois Street, San Francisco, CA 94158, USA (&#8220;FibroGen&#8221;), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany (&#8220;BI Pharma&#8221;) and&nbsp;&nbsp;on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, Amendment No. 9, effective as of November 26, 2012, Amendment No. 10, effective as of June 21, 2013, Amendment No. 11, effective as of July 9, 2013, Amendment No. 12, effective as of August 01, 2013 and subsequently assigned by BI Pharma to BI, Amendment No. 13, effective as of March 06, 2014, Amendment No. 14, effective as of February 05, 2014, Amendment No. 15, effective as of October 20, 2014, Amendment No. 16, effective as of December 08, 2014, Amendment No. 17, effective as of December 08, 2014, Amendment No. 18, effective as of February 15, 2015, Amendment No. 19, effective as of March 01, 2015, Amendment No. 20, effective as of June 01, 2015, Amendment No. 21, effective as of May 29, 2015, Amendment No. 22, effective as of&nbsp;&nbsp;April 14, 2016, Amendment No. 23, effective as of September 01, 2015 (hereinafter together the &#8220;Supply Agreement&#8221;). BI and FibroGen shall be referred to individually herein as a &#8220;Party&#8221;, and collectively as the &#8220;Parties&#8221;. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">Whereas,<font style="font-weight:normal;font-variant: normal;"> FibroGen wishes BI to [*] in compliance with the terms of the Supply Agreement as set forth in and as amended by this 24th Amendment. The activities hereunder will be performed by BI Pharma on behalf of BI. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">Now, Therefore<font style="font-weight:normal;font-variant: normal;">, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.08%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.83%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Unless otherwise defined herein, all capitalized terms and phrases used in this 24th Amendment shall have the meaning ascribed to them in the Supply Agreement.</p></td></tr></table></div>